Well reported studies of labelling issues give unfair bad press to CBD – but it is an issue the industry urgently needs to address, according to speakers at the Food and Drug Law Institute’s annual conference
Get 7 days of access to industry updates through our news analysis and regulatory alerts
"*" indicates required fields